• E-Blink

  Participated · Equity · Apr 2012

  EBlink develops wireless "FrontLink" fronthaul systems designed to enable faster deployment of 3G, 4G and future 5G networks. Its technology supports multi-gigabit connections and can act as an extension to fiber optic links. The company intends to use the new financing to introduce its Wireless Fronthaul technology on the international market. EBlink is led by Managing Director Christian Bittar, who is also one of the co-founding backers. The firm cites demand driven by traffic growth from smartphones and tablets as a driver for its solutions. Since its creation in 2005 the company has raised over €20m. E-Blink develops and manufactures the Wireless Remote Radio Head™ solution, which provides a radio link between base stations located on the ground and network antennas, eliminating the need for coaxial cables or fiber optics. The company’s products are validated and used by many mobile operators around the world. Founded in 2005 and based in Paris, France, E-Blink focuses on alternative solutions for base station deployment in mobile networks and handles both development and manufacturing. The company received a €7m equity investment and intends to use the capital for commercial development. The financing involves a government-backed investor alongside existing private investors, underscoring both public and private support for its market expansion. E-Blink designs and develops alternative solutions for the deployment of mobile network base stations. The company has developed the EB1 system, which eliminates the need for coaxial cables or short-range fiber optics on base stations. The EB1 is available for 2G and 3G operating frequencies and can be used to upgrade existing sites as well as for new installations. E-Blink is based in Boussy Saint Antoine, France, and was founded in 2005 by Alain Rolland and Christian Bittar. The company completed a €6m financing round and plans to use the funds to expand abroad and support research and development activities, according to co-founder Christian Bittar. The financing is intended to support both international expansion and continued product development.

• Presto Engineering

  Participated · Equity · Jan 2011

  Presto Engineering offers a labless model delivering product-engineering services and hardware to IDMs and fabless vendors, covering first-silicon characterization through product release and testing. The company maintains hubs with state-of-the-art lab capabilities and experienced engineers in Silicon Valley, Grenoble and Normandy and is ISO 9001 certified. Its services include RF and 3-D semiconductor integration, ATE, reliability testing, failure analysis and fault isolation. Presto is engaged in a multi-year collaboration with CEA-Leti to develop test and analysis capabilities for 3-D/TSV devices. Management says the company has demonstrated an impressive track record of revenue growth and customer momentum. The new funding will be used to strengthen RF and 3-D services from existing hubs and to support regional expansion of new hubs worldwide. Presto Engineering is a San Jose, CA-based provider of product engineering services to the semiconductor industry. It offers comprehensive chip testing and analysis services to help IDMs and fabless customers improve new device predictability and reduce time to market by complementing internal resources. The company operates a French-based subsidiary, Presto Engineering EUROPE, and plans to run a hub in Caen, France. Presto will acquire lab infrastructure in Caen from NXP Semiconductor. The company intends to invest in new RF and 3D-integration technologies. The new funding will support its European expansion and ongoing technology investments.

• Nanobiotix

  Participated · Series C · May 2010

  Nanobiotix develops therapeutic products for cancer that leverage nanotechnologies, with its lead program focused on nanoXray therapeutics. The company is entering a first-in-man clinical study of nanoXray with IGR Institut Gustave Roussy for soft tissue sarcoma as the initial indication. It has built a portfolio of industrial and academic collaborations, including projects such as Sonodrug with Philips Research and a partnership with Biotech Corp in Malaysia. Nanobiotix plans to reinforce its scientific and development teams and resources to support clinical development. The recent financing will enable the company to continue advancing its lead programs through clinical studies. Financial and operating metrics beyond the recent round were not disclosed in the article.

No current team members are available.